Gulam Khan, MD
Internal Medicine · Brooklyn, NYNPI 1265588362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Olympus America Inc. at 29.8% of the total.
Across 18 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$118
- Steris Corporation$60
- Lilly USA, LLC$50
- Endogastric Solutions, Inc$35
- Pfizer$30
- Madrigal Pharmaceuticals$30
- plus $71 from 4 others
Across 170 payments — averaging $3867.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$440K
- Sanofi US Services Inc.$119K
- F. Hoffmann-la Roche AG$64K
- Genentech, Inc.$18K
- Eli Lilly$17K
What the payments were for
- Food & beverage$395100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 6 | $118 |
| Steris Corporation | 3 | $60 |
| Lilly USA, LLC | 2 | $50 |
| Endogastric Solutions, Inc | 1 | $35 |
| Pfizer | 1 | $30 |
| Madrigal Pharmaceuticals | 1 | $30 |
| AstraZeneca | 1 | $21 |
| BETA Bionics, Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Conmed Corporation | 1 | $16 |
How this compares
$395 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 22 | $911 |
| Omeprazole | 47 | $410 |
| Famotidine | 35 | $301 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $295 |
| Pantoprazole Sodium | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Jesi RamoneBrooklyn$627K
- Manish ParikhBrooklyn$236K
- Samuel UterBrooklyn$136K
- David DoveEast Hampton$12.3M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.